SrasV1, PubMed, Checkpoint, bibRecord, 000B11

Human monoclonal antibodies as candidate therapeutics against emerging viruses.

Identifieur interne : 000B11 ( PubMed/Checkpoint ); précédent : 000B10; suivant : 000B12

Human monoclonal antibodies as candidate therapeutics against emerging viruses.

Auteurs : Yujia Jin [République populaire de Chine] ; Cheng Lei [République populaire de Chine] ; Dan Hu [République populaire de Chine] ; Dimiter S. Dimitrov [États-Unis] ; Tianlei Ying [République populaire de Chine]

Source :

Frontiers of medicine [ 2095-0225 ] ; 2017.

RBID : pubmed:29159596

Descripteurs français

KwdFr :
- Anticorps monoclonaux (pharmacologie), Antiviraux (pharmacologie), Découverte de médicament (tendances), Humains, Maladies transmissibles émergentes (traitement médicamenteux), Maladies transmissibles émergentes (virologie), Maladies virales (immunologie), Maladies virales (traitement médicamenteux), Phénomènes physiologiques viraux (), Phénomènes physiologiques viraux (immunologie).
MESH :
- immunologie : Maladies virales, Phénomènes physiologiques viraux.
- pharmacologie : Anticorps monoclonaux, Antiviraux.
- tendances : Découverte de médicament.
- traitement médicamenteux : Maladies transmissibles émergentes, Maladies virales.
- virologie : Maladies transmissibles émergentes.
- Humains, Phénomènes physiologiques viraux.

English descriptors

KwdEn :
- Antibodies, Monoclonal (pharmacology), Antiviral Agents (pharmacology), Communicable Diseases, Emerging (drug therapy), Communicable Diseases, Emerging (virology), Drug Discovery (trends), Humans, Virus Diseases (drug therapy), Virus Diseases (immunology), Virus Physiological Phenomena (drug effects), Virus Physiological Phenomena (immunology).
MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Antiviral Agents.
- drug effects : Virus Physiological Phenomena.
- drug therapy : Communicable Diseases, Emerging, Virus Diseases.
- immunology : Virus Diseases, Virus Physiological Phenomena.
- trends : Drug Discovery.
- virology : Communicable Diseases, Emerging.
- Humans.

Abstract

The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.

DOI: 10.1007/s11684-017-0596-6
PubMed: 29159596

Affiliations:

République populaire de Chine, États-Unis

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000A59
to stream PubMed, to step Curation: 000A59

Links to Exploration step

pubmed:29159596

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses.</title>
<author><name sortKey="Jin, Yujia" sort="Jin, Yujia" uniqKey="Jin Y" first="Yujia" last="Jin">Yujia Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lei, Cheng" sort="Lei, Cheng" uniqKey="Lei C" first="Cheng" last="Lei">Cheng Lei</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hu, Dan" sort="Hu, Dan" uniqKey="Hu D" first="Dan" last="Hu">Dan Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name>
<affiliation wicri:level="1"><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. dimitrdi@mail.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702</wicri:regionArea>
<wicri:noRegion>21702</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ying, Tianlei" sort="Ying, Tianlei" uniqKey="Ying T" first="Tianlei" last="Ying">Tianlei Ying</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. tlying@fudan.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:29159596</idno>
<idno type="pmid">29159596</idno>
<idno type="doi">10.1007/s11684-017-0596-6</idno>
<idno type="wicri:Area/PubMed/Corpus">000A59</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A59</idno>
<idno type="wicri:Area/PubMed/Curation">000A59</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A59</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B11</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B11</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Human monoclonal antibodies as candidate therapeutics against emerging viruses.</title>
<author><name sortKey="Jin, Yujia" sort="Jin, Yujia" uniqKey="Jin Y" first="Yujia" last="Jin">Yujia Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lei, Cheng" sort="Lei, Cheng" uniqKey="Lei C" first="Cheng" last="Lei">Cheng Lei</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hu, Dan" sort="Hu, Dan" uniqKey="Hu D" first="Dan" last="Hu">Dan Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name>
<affiliation wicri:level="1"><nlm:affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. dimitrdi@mail.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702</wicri:regionArea>
<wicri:noRegion>21702</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ying, Tianlei" sort="Ying, Tianlei" uniqKey="Ying T" first="Tianlei" last="Ying">Tianlei Ying</name>
<affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. tlying@fudan.edu.cn.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032</wicri:regionArea>
<wicri:noRegion>200032</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Frontiers of medicine</title>
<idno type="eISSN">2095-0225</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Communicable Diseases, Emerging (drug therapy)</term>
<term>Communicable Diseases, Emerging (virology)</term>
<term>Drug Discovery (trends)</term>
<term>Humans</term>
<term>Virus Diseases (drug therapy)</term>
<term>Virus Diseases (immunology)</term>
<term>Virus Physiological Phenomena (drug effects)</term>
<term>Virus Physiological Phenomena (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (pharmacologie)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Découverte de médicament (tendances)</term>
<term>Humains</term>
<term>Maladies transmissibles émergentes (traitement médicamenteux)</term>
<term>Maladies transmissibles émergentes (virologie)</term>
<term>Maladies virales (immunologie)</term>
<term>Maladies virales (traitement médicamenteux)</term>
<term>Phénomènes physiologiques viraux ()</term>
<term>Phénomènes physiologiques viraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Virus Physiological Phenomena</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Communicable Diseases, Emerging</term>
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Maladies virales</term>
<term>Phénomènes physiologiques viraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Virus Diseases</term>
<term>Virus Physiological Phenomena</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Découverte de médicament</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies transmissibles émergentes</term>
<term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Discovery</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies transmissibles émergentes</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Communicable Diseases, Emerging</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Phénomènes physiologiques viraux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29159596</PMID>
<DateCompleted><Year>2018</Year>
<Month>07</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2095-0225</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>4</Issue>
<PubDate><Year>2017</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Frontiers of medicine</Title>
<ISOAbbreviation>Front Med</ISOAbbreviation>
</Journal>
<ArticleTitle>Human monoclonal antibodies as candidate therapeutics against emerging viruses.</ArticleTitle>
<Pagination><MedlinePgn>462-470</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11684-017-0596-6</ELocationID>
<Abstract><AbstractText>The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Yujia</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lei</LastName>
<ForeName>Cheng</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hu</LastName>
<ForeName>Dan</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dimitrov</LastName>
<ForeName>Dimiter S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo><Affiliation>Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. dimitrdi@mail.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ying</LastName>
<ForeName>Tianlei</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. tlying@fudan.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>11</Month>
<Day>20</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Front Med</MedlineTA>
<NlmUniqueID>101549428</NlmUniqueID>
<ISSNLinking>2095-0217</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018406" MajorTopicYN="Y">Virus Physiological Phenomena</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ebola virus</Keyword>
<Keyword MajorTopicYN="N">MERS-CoV</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV</Keyword>
<Keyword MajorTopicYN="N">emerging infectious diseases</Keyword>
<Keyword MajorTopicYN="N">human monoclonal antibodies</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>10</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2018</Year>
<Month>7</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>11</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29159596</ArticleId>
<ArticleId IdType="doi">10.1007/s11684-017-0596-6</ArticleId>
<ArticleId IdType="pii">10.1007/s11684-017-0596-6</ArticleId>
<ArticleId IdType="pmc">PMC7088856</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Scand J Immunol. 2001 Sep;54(3):249-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11555388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1997;142(11):2249-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9672590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Rev. 1992 Mar;56(1):180-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1579109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17940980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Drug Resist. 2014 Nov 03;7:281-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25395865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2014 Oct 2;514(7520):47-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25171469</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234cm3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24786321</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1995 Oct 12;186(1):125-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7561141</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2015 Sep 15;6:8223</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26370782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23071322</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2014 Jun 25;6(242):242cm6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24964986</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2012 Jun 13;4(138):138fs18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22700952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 2000;328:430-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11075358</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 1999 Oct;93(1):5-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10497006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2011 Sep 22;477(7365):466-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21849977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2008 Jul 10;454(7201):177-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18615077</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 Mar 18;351(6279):1339-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26917593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Aug 8;500(7461):227-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23831647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1978;56(2):245</Citation>
<ArticleIdList><ArticleId IdType="pubmed">307454</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24778221</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1978 Nov 16;276(5685):269-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">714156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Eng. 1997 Nov;10(11):1303-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9514119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Aug;10(8):871-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15247913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 Sep 30;353(6307):1557-1560</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27608668</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):157-71; discussion 171-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7944335</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Biotechnol. 2011 Sep;28(5):489-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21473942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Feb;81(4):1821-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17151111</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2011 Mar 5;377(9768):849-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21084112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2014 Jun;142(6):1138-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24040779</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2013 Mar 14;495 (7440):149-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23486032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2017 Jun;23 (6):1026-1028</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28518019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12612-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12239343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 1997 Jun;15(6):553-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9181578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Rev. 1997 Apr 1;97(2):391-410</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11848876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1984 Jan 1;159(1):208-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6319530</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Rep. 2015 Sep 29;12(12):2111-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26365189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Jul;11(7):786-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15937495</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(4):e5308</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19390586</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Mar;84(6):2972-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20053739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Dec 18;371(25):2402-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25390460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24706856</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2007 Sep;7(9):715-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17703228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 1995 Dec;39(2-3):129-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8837880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(5):e5547</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19440245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 Apr 1;213(7):1124-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26715676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Oct 9;326(5950):285-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19729618</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Sep 5;301(5638):1374-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12920303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26124093</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2002 Aug;10(2):307-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12191476</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2002 Feb;4(2):185-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11880051</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):231-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17620608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16441209</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Mol Biol. 2009;525:1-27, xiii</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19252861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Biotechnol. 2016;17 (15):1348-1352</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27552847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Respir Med. 2015 Jun;9(3):327-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25790840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MBio. 2012 Nov 20;3(6):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12516-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25114257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbes Infect. 2015 Feb;17(2):109-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25498866</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1985 Jun 14;228(4705):1315-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4001944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2016 Mar 18;351(6279):1343-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26917592</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Transl Med. 2011 Oct 19;3(105):105fs6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22013121</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Jin, Yujia" sort="Jin, Yujia" uniqKey="Jin Y" first="Yujia" last="Jin">Yujia Jin</name>
</noRegion>
<name sortKey="Hu, Dan" sort="Hu, Dan" uniqKey="Hu D" first="Dan" last="Hu">Dan Hu</name>
<name sortKey="Lei, Cheng" sort="Lei, Cheng" uniqKey="Lei C" first="Cheng" last="Lei">Cheng Lei</name>
<name sortKey="Ying, Tianlei" sort="Ying, Tianlei" uniqKey="Ying T" first="Tianlei" last="Ying">Tianlei Ying</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Dimitrov, Dimiter S" sort="Dimitrov, Dimiter S" uniqKey="Dimitrov D" first="Dimiter S" last="Dimitrov">Dimiter S. Dimitrov</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:29159596
   |texte=   Human monoclonal antibodies as candidate therapeutics against emerging viruses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:29159596" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Human monoclonal antibodies as candidate therapeutics against emerging viruses.

Human monoclonal antibodies as candidate therapeutics against emerging viruses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki